# Fleury profit rises to R$96.3 million in 4Q25 as diagnostics demand grows

*Revenue climbs 12% year-on-year while EBITDA reaches R$455.9 million, supported by B2C expansion and acquisitions.*

- Published: 2026-03-05
- Updated: 2026-03-06
- Section: Insights
- Tags: Brazil healthcare companies, Brazilian healthcare sector, diagnostic medicine Brazil, Fleury, Fleury 4Q25 results, Fleury earnings, healthcare earnings Brazil, medical diagnostics Brazil
- URL: https://brazilstockguide.com/insights/fleury-4q25-results-profit/

![Fleury, Health Care](https://i0.wp.com/brazilstockguide.com/wp-content/uploads/2025/11/Fleury.jpg?fit=1024%2C690&ssl=1)

*Fleury, Health Care*

**By Brazil Stock Guide —** Fleury posted a **net profit of R$96.3 million in the fourth quarter of 2025**, a **14.7% increase compared with R$84 million in the same period a year earlier**, as Brazil’s leading diagnostic medicine groups continued to benefit from steady demand and expansion across regional markets.

**Gross revenue reached R$2.24 billion**, up **12.2% year-on-year**, while **net revenue totaled R$2.06 billion**, rising 12%. **EBITDA came in at R$455.9 million**, representing **12.5% growth**, with the **EBITDA margin broadly stable at 22.1%**.

**B2C diagnostics drive growth**

The company’s main growth engine remained the **B2C diagnostics segment**, where revenue increased **13.4% in the quarter**, including **10.2% organic growth**. The flagship **Fleury brand expanded 8.6%**, reflecting resilient demand for premium diagnostic services.

Other brands operating in the state of São Paulo posted **25.5% growth**, supported both by organic expansion and the integration of newly acquired regional networks such as **Confiance and LSL**.

Regional markets also delivered strong performance. **Minas Gerais revenue rose 21.3%**, while **Rio de Janeiro increased 14.1%**, reflecting gains in market share across multiple brands.

Operational activity also accelerated. Fleury conducted **40.9 million exams in the quarter**, an increase of **13.6% year-on-year**, while total patient visits reached **3.9 million**, up 4%.

**New services expand the platform**

Another important contributor was the **“Novos Elos” platform**, which brings together specialized outpatient services including infusion clinics, orthopedics, reproductive medicine and digital health initiatives.

Revenue in this segment **grew 24.4% to R$217.5 million**, representing roughly **10% of the company’s quarterly revenue**, highlighting Fleury’s strategy of expanding beyond traditional diagnostics.

**Margins pressured by costs and interest rates**

Despite solid revenue growth, **gross margin declined slightly to 23.8%**, mainly due to higher costs associated with laboratory materials and high-cost medication applications.

Financial expenses also increased. The company reported **net financial expenses of R$116.4 million**, reflecting the impact of Brazil’s high interest-rate environment, with the benchmark Selic rate rising to around **15% by the end of 2025**.

Even so, Fleury maintained a **comfortable leverage ratio of around 1.0x net debt to EBITDA**, well below its covenant limit, giving the company flexibility to continue pursuing acquisitions and expansion opportunities.

**Full-year performance**

For the full year, Fleury reported **gross revenue of R$9.0 billion**, up **8.2% from 2024**, with **EBITDA of R$2.14 billion** and an **EBITDA margin of 25.8%**.

**Net income totaled R$612.8 million**, broadly stable year-on-year, while operating cash flow reached **R$2.13 billion**, reflecting nearly full EBITDA conversion and the strength of the company’s operating model.

As the group approaches its **100th anniversary in 2026**, Fleury is positioning itself as one of Brazil’s most diversified healthcare platforms, combining diagnostic medicine with specialized outpatient services and digital health solutions.

---

Source: Brazil Stock Guide, https://brazilstockguide.com/insights/fleury-4q25-results-profit/
